The CCTSI, in collaboration with Venture Partners at CU Boulder, CSU Ventures, Colorado State University and the CU Anschutz NIH funded Research Evaluation and Commercialization Hubs (REACH) program presents Ask the Expert: adVentures in Innovation.
On August 9, 2021 at noon Richard C. Duke, Ph.D. will present Tying it all Together: Inventor, Biomedical Researcher, Executive and Serial Entrepreneur.
Dr. Duke has more than 20 years of experience in building, financing and managing start-up biotechnology companies based on inventions made in Colorado’s non-profit research institutions. He is currently the Principal Investigator and Co-Director of the University of Colorado Anschutz Medical Campus Research Evaluation and Commercialization Hub (REACH) and was the Founder and Chief Scientific Officer of the Colorado Institute for Drug, Device and Diagnostic Development (CID4). Dr. Duke is a Co-scientific Founder and former CEO of GlobeImmune (NASD:GBIM) and was involved in the formation and/or management of Newellink, ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, MenoGeniX, Aurora Oncology and AMP Discovery.
In addition to his entrepreneurial activities, Dr. Duke has more than 35 years of experience in biomedical research and is a tenured faculty member in the Department of Medicine (Medical Oncology) at the University of Colorado School of Medicine. He has provided independent third party research analysis in the life sciences sector to Janus Capital and to venture capital firms.
He is a graduate of McGill University (B.Sc. and M.Sc.) and the University of Colorado (Ph.D.). Dr. Duke strongly believes in the merits and opportunities that arise from building new companies based on university technologies and enjoys working with academic entrepreneurs.
This lunchtime series is designed for researchers and academics who are interested in entrepreneurship, pharmaceutical, device and technology development and innovation.
Each month, skillful interviewers will engage in an enlightening conversation with an expert, followed by a Q&A session.